The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world.
Alpha-fetoprotein (AFP) is considered as a diagnostic and prognostic tumorous marker for …

Liver metastasis, the leading cause of colorectal cancer mortality, exhibits a highly
heterogeneous and suppressive immune microenvironment. Here, we sequenced 97 …

Cancer cells selectively promote translation of specific oncogenic transcripts to facilitate
cancer survival and progression, but the underlying mechanisms are poorly understood …

In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and
stemness features. In this context, tumor cells might undergo cell fate transition in response …

Hepatocarcinogenesis involves complex genetic and cellular dysregulations which drive the
formation of hepatocellular carcinoma (HCC), the predominant form of primary liver cancer …

In this era of precision medicine, with the help of biomarkers, immunotherapy has
significantly improved prognosis of many patients with malignant tumor. Deficient mismatch …

A high rate of recurrence after curative therapy is a major challenge for the management of
hepatocellular carcinoma (HCC). Currently, no effective adjuvant therapy is available to …

Background Cuproptosis is a recently discovered mechanism of programmed cell death
caused by intracellular aggregation of mitochondrial lipoylated proteins and destabilization …

Hepatocellular carcinomas (HCCs) are highly heterogeneous malignancies with different
risk factors, including alcohol abuse, chronic hepatitis B virus (HBV) and hepatitis C virus …